Szymon Wojciech Kmiecik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Szymon Wojciech Kmiecik has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Matthias P. Mayer
Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), Heidelberg, Germany
4 shared publications - Amy E. Schade
Genetics Division, Department of Medicine, Brigham and Women’s Hospital, Boston, United States of America
1 shared publication - Beata Filip-Psurska
Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Science, Wroclaw, Poland
1 shared publication Frauke Melchior
Center for Molecular Biology of Heidelberg University (ZMBH), DKFZ-ZMBH-Alliance, Im Neuenheimer Feld 282, D-69120 Heidelberg, Germany
1 shared publication- Henrik Breitenreicher
Internal Medicine IX—Department of Clinical Pharmacology and Pharmacoepidemiology, Medical Faculty Heidelberg, Heidelberg University Hospital, Heidelberg University, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
1 shared publication - Jannis Moormann
Institute for Plant Sciences, Cluster of Excellence on Plant Sciences (CEPLAS), University of Cologne, Cologne, Germany
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (46)
The highly heat-inducible HspA6 and the thermolabile DnaJB5 are potent regulators of heat shock transcription factor 1 activity
In response to proteotoxic stress the central regulator of the heat shock response (HSR) in mammalian cells, Hsf1, trimerizes, binds DNA, and drives transcription of heat shock genes. We previously showed that Hsc70 (HspA8) assisted by its J-domain protein (JDP) cochaperone DnaJB1 dissociates Hsf1 from DNA by monomerizing the trimeric Hsf1 and thereby attenuates the HSR. Whether this feedback mechanism is specific to the HspA8–DnaJB1 pair or instead reflects a broader, isoform- and JDP-selective Hsp70 network controlling Hsf1 remained unresolved. Here, we demonstrate that of all cytonuclear Hsp70s the highly heat-inducible HspA6 is most efficient in monomerizing Hsf1 in the presence of DnaJB1 and of all cytonuclear class A and class B JDPs, only DnaJB1, DnaJB4, and DnaJB5 assist in Hsf1 monomerization. Whereas cooperation of HspA6 and HspA8 with DnaJB1 and DnaJB4 absolutely depends on Hsp70s’ C-terminal glutamate-glutamate-valine-glutamate (EEVD)-motif, cooperation with DnaJB5 does not. Consistent with these data, overproduction of EEVD-deleted HspA8 and HspA6 down-regulate the HSR in HeLa cells. DnaJB5 knockdown reduces HspA8–Hsf1 interaction under nonstress conditions revealing DnaJB5 as major targeting factor for HspA8 binding to Hsf1. On temperature upshift DnaJB5 partially unfolds and partitions into insoluble cell fractions, suggesting it is a thermosensor that allows for increased Hsf1 activity by reducing HspA8’s ability to monomerize Hsf1. During ongoing heat shock, upregulated HspA6 and HspA8 then limit the HSR presumably targeted by heat-induced DnaJB1. HspA6 knock-down and overproduction in HeLa cells suggest that HspA6 functions in preventing an overshoot of the HSR.
- 10 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (46)
Open AccessThe highly heat-inducible HspA6 and the thermolabile DnaJB5 are potent regulators of heat shock transcription factor 1 activity
In response to proteotoxic stress the central regulator of the heat shock response (HSR) in mammalian cells, Hsf1, trimerizes, binds DNA, and drives transcription of heat shock genes. We previously showed that Hsc70 (HspA8) assisted by its J-domain protein (JDP) cochaperone DnaJB1 dissociates Hsf1 from DNA by monomerizing the trimeric Hsf1 and thereby attenuates the HSR. Whether this feedback mechanism is specific to the HspA8–DnaJB1 pair or instead reflects a broader, isoform- and JDP-selective Hsp70 network controlling Hsf1 remained unresolved. Here, we demonstrate that of all cytonuclear Hsp70s the highly heat-inducible HspA6 is most efficient in monomerizing Hsf1 in the presence of DnaJB1 and of all cytonuclear class A and class B JDPs, only DnaJB1, DnaJB4, and DnaJB5 assist in Hsf1 monomerization. Whereas cooperation of HspA6 and HspA8 with DnaJB1 and DnaJB4 absolutely depends on Hsp70s’ C-terminal glutamate-glutamate-valine-glutamate (EEVD)-motif, cooperation with DnaJB5 does not. Consistent with these data, overproduction of EEVD-deleted HspA8 and HspA6 down-regulate the HSR in HeLa cells. DnaJB5 knockdown reduces HspA8–Hsf1 interaction under nonstress conditions revealing DnaJB5 as major targeting factor for HspA8 binding to Hsf1. On temperature upshift DnaJB5 partially unfolds and partitions into insoluble cell fractions, suggesting it is a thermosensor that allows for increased Hsf1 activity by reducing HspA8’s ability to monomerize Hsf1. During ongoing heat shock, upregulated HspA6 and HspA8 then limit the HSR presumably targeted by heat-induced DnaJB1. HspA6 knock-down and overproduction in HeLa cells suggest that HspA6 functions in preventing an overshoot of the HSR.
- Open Access
- 8 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1870
Validation of a UPLC-MS/MS Method for Quantifying Intracellular Olaparib Levels in Resistant Ovarian Cancer Cells
Background: Ovarian cancer remains one of the leading causes of cancer-related mortality among women and constitutes a major unmet medical need. A common treatment-limiting factor for ovarian cancer patients is resistance to Poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib. Resistance mechanisms include restoration of functional homologous recombination repair, replication fork protection, PARP1 mutations, and increased drug efflux or metabolism. Understanding these cellular and molecular mechanisms is essential for developing more effective therapeutic strategies and improving patient outcomes. Methods: In this study, patient-derived ovarian cancer cells (OC12) in which resistance to olaparib was induced by exposing the cells to increasing concentrations of the drug over multiple treatment cycles were investigated. To compare intracellular olaparib levels in sensitive and resistant cell lines, a UPLC-MS/MS method to quantify olaparib in the range of 1–300 ng/mL was developed. Results: The method was validated for selectivity, calibration curve performance, carryover, dilution integrity, precision, accuracy, matrix effect, and recovery in accordance with ICH M10 guidelines for bioanalytical method validation. Our findings revealed no significant difference in olaparib levels between resistant and sensitive OC12 cells, excluding the involvement of efflux transporters or enhanced metabolism of olaparib in the resistant OC12 ovarian cancer cells. Conclusions: These results shift the future focus toward pharmacodynamic factors as key drivers of olaparib resistance in OC12 cells. Taken together, the developed UPLC-MS/MS analytical method can be successfully applied to quantify intracellular olaparib levels and investigate the potential contribution of drug efflux mechanisms or increased metabolic activity in cells resistant to olaparib treatment.
- 8 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1870
Open AccessValidation of a UPLC-MS/MS Method for Quantifying Intracellular Olaparib Levels in Resistant Ovarian Cancer Cells
Background: Ovarian cancer remains one of the leading causes of cancer-related mortality among women and constitutes a major unmet medical need. A common treatment-limiting factor for ovarian cancer patients is resistance to Poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib. Resistance mechanisms include restoration of functional homologous recombination repair, replication fork protection, PARP1 mutations, and increased drug efflux or metabolism. Understanding these cellular and molecular mechanisms is essential for developing more effective therapeutic strategies and improving patient outcomes. Methods: In this study, patient-derived ovarian cancer cells (OC12) in which resistance to olaparib was induced by exposing the cells to increasing concentrations of the drug over multiple treatment cycles were investigated. To compare intracellular olaparib levels in sensitive and resistant cell lines, a UPLC-MS/MS method to quantify olaparib in the range of 1–300 ng/mL was developed. Results: The method was validated for selectivity, calibration curve performance, carryover, dilution integrity, precision, accuracy, matrix effect, and recovery in accordance with ICH M10 guidelines for bioanalytical method validation. Our findings revealed no significant difference in olaparib levels between resistant and sensitive OC12 cells, excluding the involvement of efflux transporters or enhanced metabolism of olaparib in the resistant OC12 ovarian cancer cells. Conclusions: These results shift the future focus toward pharmacodynamic factors as key drivers of olaparib resistance in OC12 cells. Taken together, the developed UPLC-MS/MS analytical method can be successfully applied to quantify intracellular olaparib levels and investigate the potential contribution of drug efflux mechanisms or increased metabolic activity in cells resistant to olaparib treatment.
- 11 May 2023
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 48 (6) , 491-494
Crafting figures to describe cellular processes
- 11 May 2023
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 48 (6) , 491-494
Crafting figures to describe cellular processes
- Top Cited Papers
- 1 March 2022
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 47 (3) , 218-234
Molecular mechanisms of heat shock factor 1 regulation
- 1 March 2022
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 47 (3) , 218-234
Top Cited PapersMolecular mechanisms of heat shock factor 1 regulation
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100324
Heat shock transcription factor 1 is SUMOylated in the activated trimeric state
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100324
Open AccessHeat shock transcription factor 1 is SUMOylated in the activated trimeric state
- Open Access
- 3 June 2020
- Published by Springer Nature in The EMBO Journal
- Vol. 39 (14) , e104096
Feedback regulation of heat shock factor 1 (Hsf1) activity by Hsp70‐mediated trimer unzipping and dissociation from DNA
The heat shock response is a universal transcriptional response to proteotoxic stress orchestrated by heat shock transcription factor Hsf1 in all eukaryotic cells. Despite over 40 years of intense research, the mechanism of Hsf1 activity regulation remains poorly understood at the molecular level. In metazoa, Hsf1 trimerizes upon heat shock through a leucine‐zipper domain and binds to DNA. How Hsf1 is dislodged from DNA and monomerized remained enigmatic. Here, using purified proteins, we demonstrate that unmodified trimeric Hsf1 is dissociated from DNA in vitro by Hsc70 and DnaJB1. Hsc70 binds to multiple sites in Hsf1 with different affinities. Hsf1 trimers are monomerized by successive cycles of entropic pulling, unzipping the triple leucine‐zipper. Starting this unzipping at several protomers of the Hsf1 trimer results in faster monomerization. This process directly monitors the concentration of Hsc70 and DnaJB1. During heat shock adaptation, Hsc70 first binds to a high‐affinity site in the transactivation domain, leading to partial attenuation of the response, and subsequently, at higher concentrations, Hsc70 removes Hsf1 from DNA to restore the resting state.
- 3 June 2020
- Published by Springer Nature in The EMBO Journal
- Vol. 39 (14) , e104096
Open AccessFeedback regulation of heat shock factor 1 (Hsf1) activity by Hsp70‐mediated trimer unzipping and dissociation from DNA
The heat shock response is a universal transcriptional response to proteotoxic stress orchestrated by heat shock transcription factor Hsf1 in all eukaryotic cells. Despite over 40 years of intense research, the mechanism of Hsf1 activity regulation remains poorly understood at the molecular level. In metazoa, Hsf1 trimerizes upon heat shock through a leucine‐zipper domain and binds to DNA. How Hsf1 is dislodged from DNA and monomerized remained enigmatic. Here, using purified proteins, we demonstrate that unmodified trimeric Hsf1 is dissociated from DNA in vitro by Hsc70 and DnaJB1. Hsc70 binds to multiple sites in Hsf1 with different affinities. Hsf1 trimers are monomerized by successive cycles of entropic pulling, unzipping the triple leucine‐zipper. Starting this unzipping at several protomers of the Hsf1 trimer results in faster monomerization. This process directly monitors the concentration of Hsc70 and DnaJB1. During heat shock adaptation, Hsc70 first binds to a high‐affinity site in the transactivation domain, leading to partial attenuation of the response, and subsequently, at higher concentrations, Hsc70 removes Hsf1 from DNA to restore the resting state.
- Open Access
- 30 July 2017
- Published by Walter de Gruyter GmbH in Postępy Higieny I Medycyny Doświadczalnej
- Vol. 71 (1) , 618-623
Methotrexate and epirubicin conjugates as potential antitumor drugs
Introduction: The use of hybrid molecules has become one of the most significant approaches in new cytotoxic drug design. This study describes synthesis and characterization of conjugates consisting of two well-known and characterized chemotherapeutic agents: methotrexate (MTX) and epirubicin (EPR). The synthesized conjugates combine two significant anticancer strategies: combinatory therapy and targeted therapy. These two drugs were chosen because they have different mechanisms of action, which can increase the anticancer effect of the obtained conjugates. MTX, which is a folic acid analog, has high cytotoxic properties and can serve as a targeting moiety that can reach folate receptors (FRs) overexpresing tumor cells. Combination of nonselective drugs such as EPR with MTX can increase the selectivity of the obtained conjugates, while maintaining the high cytotoxic properties.Materials and methods: Conjugates were purified by RP-HPLC and the structure was investigated by MS and MS/MS methods. The effect of the conjugates on proliferation of LoVo, LoVo/Dx, MCF-7 and MV-4-11 human cancer cell lines was determined by SRB or MTT assay.Results: The conjugation reaction results in the formation of monosubstituted (α, γ) and disubstituted MTX derivatives. In vitro proliferation data demonstrate that the conjugates synthesized in our study show lower cytotoxic properties than both chemotherapeutics used alone.Discussion: Epirubicin cytotoxicity was not observed in obtained conjugates. Effective drugs release after internalization needs further investigation
- 30 July 2017
- Published by Walter de Gruyter GmbH in Postępy Higieny I Medycyny Doświadczalnej
- Vol. 71 (1) , 618-623
Open AccessMethotrexate and epirubicin conjugates as potential antitumor drugs
Introduction: The use of hybrid molecules has become one of the most significant approaches in new cytotoxic drug design. This study describes synthesis and characterization of conjugates consisting of two well-known and characterized chemotherapeutic agents: methotrexate (MTX) and epirubicin (EPR). The synthesized conjugates combine two significant anticancer strategies: combinatory therapy and targeted therapy. These two drugs were chosen because they have different mechanisms of action, which can increase the anticancer effect of the obtained conjugates. MTX, which is a folic acid analog, has high cytotoxic properties and can serve as a targeting moiety that can reach folate receptors (FRs) overexpresing tumor cells. Combination of nonselective drugs such as EPR with MTX can increase the selectivity of the obtained conjugates, while maintaining the high cytotoxic properties.Materials and methods: Conjugates were purified by RP-HPLC and the structure was investigated by MS and MS/MS methods. The effect of the conjugates on proliferation of LoVo, LoVo/Dx, MCF-7 and MV-4-11 human cancer cell lines was determined by SRB or MTT assay.Results: The conjugation reaction results in the formation of monosubstituted (α, γ) and disubstituted MTX derivatives. In vitro proliferation data demonstrate that the conjugates synthesized in our study show lower cytotoxic properties than both chemotherapeutics used alone.Discussion: Epirubicin cytotoxicity was not observed in obtained conjugates. Effective drugs release after internalization needs further investigation